Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

Summary

“Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the arthritis therapeutics market from 2001 to 2009, forecast forward to 2016.
- Market characterization of the arthritis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development. .
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global arthritis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1.1 List of Tables 5
1.2 List of Figures 7
2 Arthritis Therapeutics Market to 2016: Introduction 9
2.1 GBI Research Report Guidance 9
3 Arthritis Therapeutics Market to 2016: Market Overview 10
3.1 Introduction 10
3.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 10
3.2.1 Revenue 10
3.2.2 Annual Cost of Treatment (ACT) 12
3.2.3 Treatment Usage Patterns 13
4 Arthritis Therapeutics Market to 2016: Geographical Landscape 19
4.1 Revenue Analysis by Geography 19
4.2 The US 21
4.2.1 Revenue 21
4.2.2 Annual Cost of Treatment 23
4.2.3 Treatment Usage Patterns 25
4.3 Top Five Countries of Europe 31
4.3.1 Revenue 31
4.3.2 Annual Cost of Treatment 32
4.3.3 Treatment Usage Patterns 33
4.4 Japan 39
4.4.1 Revenue 39
4.4.2 Annual Cost of Treatment 40
4.4.3 Treatment Usage Patterns 41
5 Arthritis Therapeutics Market to 2016: Therapeutic Landscape 47
5.1 Osteoarthritis Therapeutics Market 47
5.1.1 Introduction 47
5.1.2 Revenue 47
5.1.3 Annual Cost of Treatment 49
5.1.4 Treatment Usage Patterns 50
5.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 56
5.2.1 Drivers for the Osteoarthritis Therapeutics Market 56
5.2.2 Barriers for the Osteoarthritis Therapeutics Market 57
5.3 Opportunity and Unmet Need 57
5.4 Rheumatoid Arthritis Therapeutics Market 57
5.4.1 Introduction 57
5.4.2 Revenue 58
5.4.3 Annual Cost of Treatment 59
5.4.4 Treatment Usage Patterns 60
5.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 66
5.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 66
5.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 67
5.6 Opportunity and Unmet Need 67
5.7 Psoriatic Arthritis Therapeutics Market 67
5.7.1 Introduction 67
5.7.2 Revenue 68
5.7.3 Annual Cost of Treatment 69
5.7.4 Treatment Usage Patterns 70
5.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 76
5.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 76
5.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 77
5.9 Opportunity and Unmet Need 77
6 Arthritis Therapeutics Market to 2016: Pipeline Analysis 78
6.1 Introduction 78
6.1.1 Research and Development Pipeline – Osteoarthritis 79
6.1.2 Research and Development Pipeline – Rheumatoid Arthritis 85
6.1.3 Research and Development Pipeline – Psoriatic Arthritis 95
6.2 Profiles of Promising Drugs in the Arthritis Therapeutics Market 97
6.2.1 CG5503 97
6.2.2 Vicodin CR 97
6.2.3 T-614 (iguratimod) 98
6.2.4 AIN457 99
6.2.5 Alefacept + Methotrexate 99
6.2.6 Apremilast 100
6.2.7 Cimzia 101
6.2.8 CP-690550 102
6.2.9 Fludarabine 103
6.2.10 PG102 103
6.2.11 Rituxan + Methotrexate 104
7 Arthritis Therapeutics Market to 2016: Competitive Landscape 106
7.1 Evolving Competitive Landscape 106
7.1.1 Major Players 106
7.2 Market Share Analysis 107
7.3 Competitive Profiling 107
7.3.1 Abbott Laboratories 107
7.3.2 Amgen Inc. 109
7.3.3 Johnson & Johnson 110
7.3.4 Pfizer 111
7.3.5 Novartis AG 113
7.3.6 Eli Lilly and Company 114
7.3.7 Boehringer Ingelheim GmbH 115
7.3.8 Lupin 116
8 Arthritis Therapeutics Market to 2016: M&A Landscape 117
8.1 Mergers and Acquisitions 117
8.1.1 Pfizer Acquires Wyeth 117
8.1.2 Cephalon Acquires Arana Therapeutics 118
8.1.3 Aspen Pharmacare Acquires Sigma Pharmaceuticals 118
8.1.4 Deals by Geography 118
8.1.5 Deals by Value 119
9 Arthritis Therapeutics Market to 2016: Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 121
9.3.3 Primary Research 122
9.3.4 Forecasts 122
9.3.5 Expert Panel Validation 124
9.4 Contact Us 125
9.5 Disclaimer 125
9.6 Sources 125

1.1 List of Tables
Table 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 11
Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 11
Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 13
Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 13
Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 14
Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 14
Table 7: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2001-2009 19
Table 8: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2009-2016 20
Table 9: Arthritis Therapeutics Market, The US, Revenue ($bn), 2001-2009 22
Table 10: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2009-2016 22
Table 11: Arthritis Therapeutics Market, The US, Annual Cost of Treatment($), 2001-2009 24
Table 12: Arthritis Therapeutics Market, The US, Annual Cost of Treatment($), 2009-2016 24
Table 13: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009 26
Table 14: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016 26
Table 15: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2001-2009 31
Table 16: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2009-2016 31
Table 17: Arthritis Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2001-2009 32
Table 18: Arthritis Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2009-2016 33
Table 19: Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2001-2009 34
Table 20: Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2009-2016 34
Table 21: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2001-2009 39
Table 22: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2009-2016 39
Table 23: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2001-2009 40
Table 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2009-2016 40
Table 25: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2009 42
Table 26: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2009-2016 42
Table 27: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 48
Table 28: Osteoarthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2016 48
Table 29: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 49
Table 30: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 49
Table 31: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 51
Table 32: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 52
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 58
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2016 58
Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 59
Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment($), 2009-2016 60
Table 37: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009 61
Table 38: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016 62
Table 39: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($m), 2001-2009 68
Table 40: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016 68
Table 41: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 69
Table 42: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 69
Table 43: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2009 71
Table 44: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2009-2016 72
Table 45: Arthritis Therapeutics, Osteoarthritis Pipeline, Discovery Stage Molecules, 2010 80
Table 46: Arthritis Therapeutics- Osteoarthritis Pipeline, Preclinical Molecules, 2010 81
Table 47: Arthritis Therapeutics- Osteoarthritis Pipeline, Phase I Molecules, 2010 82
Table 48: Arthritis Therapeutics- Osteoarthritis Pipeline, Phase II Molecules, 2010 83
Table 49: Arthritis Therapeutics- Osteoarthritis Pipeline, Phase III Molecules, 2010 84
Table 50: Arthritis Therapeutics- Osteoarthritis Pipeline, Filed Molecules, 2010 85
Table 51: Arthritis Therapeutics-Rheumatoid Arthritis Pipeline, Discovery Stage Molecules, 2010 86
Table 52: Arthritis Therapeutics-Rheumatoid Arthritis Pipeline, Preclinical Molecules, 2010 87
Table 53: Arthritis Therapeutics-Rheumatoid Arthritis Pipeline, Phase I Molecules, 2010 89
Table 54: Arthritis Therapeutics- Rheumatoid Arthritis Pipeline, Phase II Molecules, 2010 91
Table 55: Arthritis Therapeutics- Rheumatoid Arthritis Pipeline, Phase III Molecules, 2010 94
Table 56: Arthritis Therapeutics-Rheumatoid Arthritis Pipeline, Filed Molecules, 2010 95
Table 57: Arthritis Therapeutics- Psoriatic Arthritis Pipeline, Phase I Molecules, 2010 96
Table 58: Arthritis Therapeutics- Psoriatic Arthritis Pipeline, Phase II Molecules, 2010 96
Table 59: Arthritis Therapeutics- Psoriatic Arthritis Pipeline, Phase III Molecules, 2010 96
Table 60: Arthritis Therapeutics Market, Global, Major M&A Deals, 2008-2010 117

1.2 List of Figures
Figure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 10
Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 12
Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2016 13
Figure 4: Arthritis Therapeutics Market, Global, Diseased Population (millions), 2001-2016 15
Figure 5: Arthritis Therapeutics Market, Global, Treatment Seeking Population (millions), 2001-2016 16
Figure 6: Arthritis Therapeutics Market, Global, Diagnosis Population (millions), 2001-2016 17
Figure 7: Arthritis Therapeutics Market, Global, Prescription Population (millions), 2001-2016 18
Figure 8: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2001-2016 19
Figure 9: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2001-2016 21
Figure 10: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2001-2016 23
Figure 11: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2016 25
Figure 12: Arthritis Therapeutics Market, the US, Diseased Population (millions), 2001-2016 27
Figure 13: Arthritis Therapeutics Market, the US, Treatment Seeking Population (million), 2001-2016 28
Figure 14: Arthritis Therapeutics Market, The US, Diagnosis Population (million), 2001-2016 29
Figure 15: Arthritis Therapeutics Market, The US, Prescription Population (millions), 2001-2016 30
Figure 16: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2001-2016 31
Figure 17: Arthritis Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2001-2016 32
Figure 18: Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2001-2016 33
Figure 19: Arthritis Therapeutics Market, Top Five Countries in the EU, Diseased Population (millions), 2001-2016 35
Figure 20: Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Seeking Population (millions), 2001-2016 36
Figure 21: Arthritis Therapeutics Market, Top Five Countries in the EU, Diagnosis Population (million), 2001-2016 37
Figure 22: Arthritis Therapeutics Market, Top Five Countries in the EU, Prescription Population (millions), 2001-2016 38
Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2001-2016 39
Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2001-2016 40
Figure 25: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-2016 41
Figure 26: Arthritis Therapeutics Market, Japan, Diseased Population (millions), 2001-2016 43
Figure 27: Arthritis Therapeutics Market, Japan, Treatment Seeking Population (millions), 2001-2016 44
Figure 28: Arthritis Therapeutics Market, Japan, Diagnosis Population (millions), 2001-2016 45
Figure 29: Arthritis Therapeutics Market, Japan, Prescription Population (millions), 2001-2016 46
Figure 30: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 48
Figure 31: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 49
Figure 32: Osteoarthritis Therapeutics Market, Global, Drivers and Restraints, 2009-2016 50
Figure 33: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2016 51
Figure 34: Osteoarthritis Therapeutics Market, Global, Diseased Population (millions), 2001-2016 52
Figure 35: Osteoarthritis Therapeutics Market, Global, Treatment Seeking Population (millions), 2001-2016 53
Figure 36: Osteoarthritis Therapeutics Market, Global, Diagnosis Population (millions), 2001-2016 54
Figure 37: Osteoarthritis Therapeutics Market, Global, Prescription Population (millions), 2001-2016 55
Figure 38: Osteoarthritis Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016 56
Figure 39: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016 58
Figure 40: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 59
Figure 41: Rheumatoid Arthritis Therapeutics Market, Global, Drivers and Restraints, 2009-2016 60
Figure 42: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2016 61
Figure 43: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population (millions), 2001-2016 62
Figure 44: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population (millions), 2001-2016 63
Figure 45: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population (millions), 2001-2016 64
Figure 46: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population (millions), 2001-2016 65
Figure 47: Rheumatoid Arthritis, Market Drivers and Barriers, 2009-2016 66
Figure 48: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016 68
Figure 49: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 69
Figure 50: Psoriatic Arthritis Therapeutics Market, Global, Drivers and Restraints, 2009-2016 70
Figure 51: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2001-2016 71
Figure 52: Psoriatic Arthritis Therapeutics Market, Global, Diseased Population (thousands), 2001-2016 72
Figure 53: Psoriatic Arthritis Therapeutics Market, Global, Treatment Seeking Population (thousands), 2001-2016 73
Figure 54: Psoriatic Arthritis Therapeutics Market, Global, Diagnosis Population (thousands), 2001-2016 74
Figure 55: Psoriatic Arthritis Therapeutics Market, Global, Prescription Population (thousands), 2001-2016 75
Figure 56: Psoriatic Arthritis Therapeutics Market, Global, Drivers and Barriers, 2009-2016 76
Figure 57: Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2010 78
Figure 58: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 79
Figure 59: Osteoarthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2010 79
Figure 60: Rheumatoid Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2010 85
Figure 61: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase in Psoriatic Arthritis Therapeutics Market (%), 2010 95
Figure 62: Arthritis Therapeutics Market, Global, Top 10 Companies Sales ($bn), 2009 106
Figure 63: SWOT Analysis of Abbott 108
Figure 64: SWOT Analysis of Amgen Inc. 109
Figure 65: SWOT Analysis of Johnson & Johnson 110
Figure 66: SWOT Analysis of Pfizer 112
Figure 67: SWOT Analysis of Novartis AG 113
Figure 68: SWOT Analysis of Eli-lilly 114
Figure 69: SWOT Analysis of Boehringer Ingelheim GmbH 115
Figure 70: SWOT Analysis of Lupin Limited 116
Figure 71: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-2010 118
Figure 72: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Value (%), 2008-2010 119
Figure 73: GBI Research Market Forecasting Model 124

Abbott Laboratories
Amgen Inc.
Johnson & Johnson
Pfizer
Novartis AG
Eli Lilly and Company
Boehringer Ingelheim GmbH
Lupin